---
title: "Key facts: Novartis wins EU OK for Rhapsido; builds Morrisville API site"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284858814.md"
description: "Novartis has received EU approval for Rhapsido (remibrutinib) for adults with chronic spontaneous urticaria resistant to H1-antihistamines, showing reduced itch and hives in Phase 3 trials. The company is expanding its U.S. operations with a new research center in San Diego and three radioligand therapy plants. Additionally, Novartis is constructing a 56,200 sq ft API plant in Morrisville, NC, as part of its $23B U.S. expansion plan."
datetime: "2026-05-01T02:04:51.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284858814.md)
  - [en](https://longbridge.com/en/news/284858814.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284858814.md)
---

# Key facts: Novartis wins EU OK for Rhapsido; builds Morrisville API site

-   Novartis got EU approval for Rhapsido (remibrutinib) for adults with chronic spontaneous urticaria resistant to H1-antihistamines; Phase 3 trials showed reduced itch, hives and urticaria activity.1
-   Novartis expanded U.S. capacity in 2026: new San Diego research center, ongoing Cambridge discovery, and three radioligand therapy plants in Denton (TX), Winter Park (FL), and Carlsbad (CA).2
-   Novartis (NOVN) is building a 56,200 sq ft API plant in Morrisville, NC, to make APIs for tablets, capsules and RNA therapeutics; it's the seventh facility in its $23B U.S. buildout.3

### Related Stocks

- [NOT.DE](https://longbridge.com/en/quote/NOT.DE.md)
- [NVS.US](https://longbridge.com/en/quote/NVS.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)

## Related News & Research

- [Eton Pharmaceuticals Adds Another 2026 Launch As It Secures U.S. Rights To IMPAVIDO](https://longbridge.com/en/news/287025596.md)
- [NeOnc Advances Glioma Programs and Strengthens Financial Position](https://longbridge.com/en/news/286826865.md)
- [Skye Bioscience opens higher-dose Cohort 2 in nimacimab obesity Phase 2a study](https://longbridge.com/en/news/287053007.md)
- [<![CDATA[Regeneron Enters $2.3 Billion Collaboration with Parabilis Medicines to Discover & Develop Multiple Therapeutic Candidates]]>](https://longbridge.com/en/news/286787081.md)
- [Corvus Pharmaceuticals presents Phase 1 soquelitinib data showing durable remissions, favorable safety](https://longbridge.com/en/news/286404245.md)